MedTrace Logo

Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution

NCT03421015 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2026-05-22

No results posted yet for this study

Summary

Developing a genetic study on localized or locally advanced prostate cancer. The aim of the study is to identify genomic alteration predictive of metastatic recurrence in the context of primary heterogeneity, by using the next generation sequencing (NGS) techniques.

Identifying such biomarkers may be useful to detect a higher relapse risk, and thus lower the mortality rate.

Conditions

  • Prostatic Neoplasms

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    collaborator OTHER

  • New York Presbyterian Hospital

    collaborator OTHER

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Arnauld Villers, MD,PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03421015 on ClinicalTrials.gov